Q3 2025 Pacira Biosciences Inc Earnings Call Transcript
Key Points
- Pacira BioSciences Inc (PCRX) reported a 6% year-over-year increase in revenues, driven by strong performance from EXPAREL and iovera.
- The company achieved a 9% increase in export demand, marking the highest quarterly growth in over three years.
- Pacira BioSciences Inc (PCRX) improved its manufacturing efficiencies, leading to favorable gross margins and an increase in full-year guidance.
- The company expanded its clinical pipeline by in-licensing AMT-143, a long-acting non-opioid analgesic, aligning with its 5x30 growth strategy.
- Pacira BioSciences Inc (PCRX) solidified its exclusivity with the listing of its 21st EXPAREL patent in the FDA's Orange Book.
- ZILRETTA's acceleration has been slower than anticipated, impacting overall revenue growth.
- The shift in vial mix and discounting from the third GPO going live resulted in a slightly higher than expected single-digit year-over-year impact on net selling price.
- Non-GAAP SG&A expenses increased significantly to $81.7 million, up from $65 million last year, due to investments in commercial and market access initiatives.
- The company faces challenges in gaining faster adoption of EXPAREL in larger hospitals due to more decision-makers and implementation complexities.
- Despite strong volume growth, the gap between volume and revenue growth remains due to pricing and discounting strategies.
Good day, and thank you for standing by. Welcome to the Pacira BioSciences third-quarter earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Susan Mesco. Please go ahead.
Thank you. Good afternoon, everyone. Welcome to today's conference call to discuss our third-quarter 2025 financial results. Joining me are Frank Lee, Chief Executive Officer; Brendan Teehan, Chief Commercial Officer; and Shawn Cross, Chief Financial Officer. Jonathan Slonin, our Chief Medical Officer, is also here for our question-and-answer session.
Before we begin, let me remind you that this call will include forward-looking statements subject to the Safe Harbor provisions of federal securities laws. Such statements represent our judgment as of today and may involve risks and uncertainties. This may cause our actual results, performance, or achievements to differ materially.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
